Charles M. Perou
University of North Carolina at Chapel Hill
H-index: 180
North America-United States
Top articles of Charles M. Perou
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
BIRC5 expression by race, age and clinical factors in breast cancer patients | Breast Cancer Research | Alina M Hamilton Andrea Walens Sarah C Van Alsten Linnea T Olsson Joseph Nsonwu-Farley | 2024/3/21 |
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy | npj Breast Cancer | Tomás Pascual Aranzazu Fernandez-Martinez Yash Agrawal Adam D Pfefferle Nuria Chic | 2024/3/6 |
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities | Nature Cancer | Yi-Zhou Jiang Ding Ma Xi Jin Yi Xiao Ying Yu | 2024/2/12 |
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their … | JAMA oncology | Cynthia X Ma Vera J Suman Souzan Sanati Kiran Vij Meenakshi Anurag | 2024/1/18 |
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer | Clinical Cancer Research | Yoo Jane Han Siyao Liu Ashley Hardeman Padma Sheila Rajagopal Jeffrey Mueller | 2024/5/1 |
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis | Nature | Min-Guk Cho Rashmi J Kumar Chien-Chu Lin Joshua A Boyer Jamshaid A Shahir | 2024/1/10 |
Research autopsy programmes in oncology: shared experience from 14 centres across the world | The Journal of Pathology | Tatjana Geukens Marion Maetens Jody E Hooper Steffi Oesterreich Adrian V Lee | 2024/3/29 |
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) | Clinical Cancer Research | Holly Tovey Orsolya Sipos Joel S Parker Katherine A Hoadley Jelmar Quist | 2023/9/15 |
Gene-expression profiling to decipher breast cancer inter-and intratumor heterogeneity | Alexander Swarbrick Aranzazu Fernandez-Martinez Charles M Perou | 2023/5/3 | |
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer | The Journal of clinical investigation | Na Zhao Elena B Kabotyanski Alexander B Saltzman Anna Malovannaya Xueying Yuan | 2023/12/15 |
Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications | medRxiv | Stephane Wenric James M Davison John Guittar Gregory M Mayhew Kirk D Beebe | 2023/2/24 |
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer | Nature communications | Aleix Prat Fara Brasó-Maristany Olga Martínez-Sáez Esther Sanfeliu Youli Xia | 2023/3/1 |
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry | Genome medicine | Stefanie H Mueller Alvina G Lai Maria Valkovskaya Kyriaki Michailidou Manjeet K Bolla | 2023/1/26 |
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes | JOURNAL OF CLINICAL ONCOLOGY | Joel S Parker Michael Mullins Maggie CU Cheang Samuel Leung David Voduc | 2023/9/10 |
Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors | Clinical Cancer Research | Hyunsoo Kim Austin A Whitman Kamila Wisniewska Rasha T Kakati Susana Garcia-Recio | 2023/12/1 |
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer | Nature communications | Zhe Jiang YoungJun Ju Amjad Ali Philip ED Chung Patryk Skowron | 2023/7/18 |
Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming | Cancer Research Communications | Marni B McClure Yasunori Kogure Naser Ansari-Pour Yuki Saito Hann-Hsiang Chao | 2023/2/16 |
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence | NPJ Breast Cancer | Frederick M Howard James Dolezal Sara Kochanny Galina Khramtsova Jasmine Vickery | 2023/4/14 |
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | JAMA Network Open | Paola Zagami Aranzazu Fernandez-Martinez Naim U Rashid Katherine A Hoadley Patricia A Spears | 2023/12/1 |
Assessment of a genomic assay in patients with erbb2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab | JAMA oncology | Coralia Bueno-Muiño Isabel Echavarría Sara López-Tarruella Marta Roche-Molina María del Monte-Millán | 2023/6/1 |
Co-Authors
